Free Trial

Evofem Biosciences (EVFM) Competitors

Evofem Biosciences logo
$0.01 0.00 (0.00%)
As of 07/3/2025 11:39 AM Eastern

EVFM vs. MTNB, GLTO, MBIO, SNGX, MBRX, RDHL, INM, TTNP, PLRZ, and EVOK

Should you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Matinas Biopharma (MTNB), Galecto (GLTO), Mustang Bio (MBIO), Soligenix (SNGX), Moleculin Biotech (MBRX), Redhill Biopharma (RDHL), InMed Pharmaceuticals (INM), Titan Pharmaceuticals (TTNP), Polyrizon (PLRZ), and Evoke Pharma (EVOK). These companies are all part of the "pharmaceutical products" industry.

Evofem Biosciences vs. Its Competitors

Evofem Biosciences (NASDAQ:EVFM) and Matinas Biopharma (NYSE:MTNB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

In the previous week, Evofem Biosciences had 1 more articles in the media than Matinas Biopharma. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for Matinas Biopharma. Evofem Biosciences' average media sentiment score of 0.00 equaled Matinas Biopharma'saverage media sentiment score.

Company Overall Sentiment
Evofem Biosciences Neutral
Matinas Biopharma Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evofem Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Matinas Biopharma
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Matinas Biopharma has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Matinas Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Evofem Biosciences-46.42% -91.97% -61.93%
Matinas Biopharma N/A -123.06%-94.28%

Evofem Biosciences has higher revenue and earnings than Matinas Biopharma. Matinas Biopharma is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem Biosciences$11.39M0.10$52.98M-$0.05-0.20
Matinas BiopharmaN/AN/A-$22.94M-$3.86-0.24

0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 11.8% of Matinas Biopharma shares are owned by institutional investors. 0.2% of Evofem Biosciences shares are owned by company insiders. Comparatively, 4.6% of Matinas Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Evofem Biosciences has a beta of -0.92, meaning that its share price is 192% less volatile than the S&P 500. Comparatively, Matinas Biopharma has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.

Summary

Evofem Biosciences beats Matinas Biopharma on 7 of the 12 factors compared between the two stocks.

Get Evofem Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVFM vs. The Competition

MetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.19M$839.47M$5.55B$9.04B
Dividend YieldN/A4.84%5.22%4.00%
P/E Ratio-0.021.3727.6420.24
Price / Sales0.10228.55417.15117.30
Price / CashN/A23.4436.8958.10
Price / Book0.006.328.035.67
Net Income$52.98M-$27.99M$3.18B$249.21M
7 Day PerformanceN/A2.10%2.93%3.28%
1 Month PerformanceN/A9.39%1.72%3.95%
1 Year PerformanceN/A11.51%34.39%20.98%

Evofem Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVFM
Evofem Biosciences
0.5955 of 5 stars
$0.01
flat
N/A+4.2%$1.19M$11.39M-0.02120News Coverage
Gap Up
MTNB
Matinas Biopharma
N/A$0.89
-3.3%
N/AN/A$4.53MN/A-0.1830
GLTO
Galecto
3.3962 of 5 stars
$3.41
-0.3%
$10.00
+193.3%
-72.4%$4.52MN/A-0.2240Negative News
Gap Down
MBIO
Mustang Bio
1.0202 of 5 stars
$0.96
-6.4%
N/A-95.1%$4.47MN/A-0.01100
SNGX
Soligenix
1.505 of 5 stars
$1.31
-3.7%
N/A-43.1%$4.44M$120K-0.3120News Coverage
Gap Down
MBRX
Moleculin Biotech
3.1545 of 5 stars
$0.30
-3.3%
$4.00
+1,224.9%
-90.0%$4.41MN/A0.0020Positive News
RDHL
Redhill Biopharma
N/A$1.94
+4.3%
N/A-99.1%$4.26M$8.04M0.00210
INM
InMed Pharmaceuticals
1.0728 of 5 stars
$3.25
-3.8%
N/A-44.9%$4.08M$4.60M-0.2710News Coverage
Analyst Upgrade
Gap Up
TTNP
Titan Pharmaceuticals
0.3004 of 5 stars
$4.20
-4.5%
N/A-17.1%$4.02M$180K-0.9210
PLRZ
Polyrizon
N/A$0.74
0.0%
N/AN/A$3.94MN/A0.00N/ANews Coverage
EVOK
Evoke Pharma
N/A$2.60
-1.1%
N/A-58.3%$3.92M$10.25M-0.914Positive News

Related Companies and Tools


This page (NASDAQ:EVFM) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners